Harnessing oncolytic virus-mediated immunity
Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-onco...
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
Frontiers Media SA
2015
|
| Series: | Frontiers Research Topics
|
| Subjects: | |
| Online Access: | Open Access: DOAB, download the publication Open Access: DOAB: description of the publication |
| LEADER | 02423namaa2200469uu 4500 | ||
|---|---|---|---|
| 001 | doab49124 | ||
| 003 | oapen | ||
| 005 | 20210211 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 210211s2015 xx |||||o ||| 0|eng d | ||
| 020 | |a 978-2-88919-450-6 | ||
| 020 | |a 9782889194506 | ||
| 024 | 7 | |a 10.3389/978-2-88919-450-6 |2 doi | |
| 040 | |a oapen |c oapen | ||
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 720 | 1 | |a Volker Schirrmacher |4 aut | |
| 720 | 1 | |a Philippe Fournier |4 aut | |
| 245 | 0 | 0 | |a Harnessing oncolytic virus-mediated immunity |
| 260 | |b Frontiers Media SA |c 2015 | ||
| 300 | |a 1 online resource (110 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Frontiers Research Topics | |
| 506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
| 520 | |a Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-oncolytic immune response continues to mediate tumor destruction and retards progression of the disease. For a long time, the therapeutic efficacy was thought to depend mainly on the direct viral oncolysis based on their tumor selective replication and killing activities. But the post-oncolytic anti-tumor activity induced by the OV therapy is also a key factor for an efficient therapeutic activity. The topic adresses various strategies how to optimize OVs anti-tumor activity. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a anti-tumor activity | ||
| 653 | |a anti-viral response | ||
| 653 | |a immunotherapeutic approaches | ||
| 653 | |a immunovirotherapy | ||
| 653 | |a oncolytic virotherapy | ||
| 653 | |a oncolytic virus | ||
| 653 | |a tumor-associated antigen | ||
| 793 | 0 | |a DOAB Library. | |
| 856 | 4 | 0 | |u http://journal.frontiersin.org/researchtopic/1613/harnessing-oncolytic-virus-mediated-antitumor-immunity |7 0 |z Open Access: DOAB, download the publication |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/49124 |7 0 |z Open Access: DOAB: description of the publication |